case / 03 Dec 2021

Setterwalls has advised Alligator Bioscience in connection with rights issue of approximately SEK 257 million

Responsive image

Setterwalls has advised Alligator Bioscience AB (“Alligator”), listed on Nasdaq Stockholm, in connection with a rights issue of shares of approximately SEK 257 million. The rights issue was subscribed to approximately 121 per cent.

Alligator is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator’s shares are listed on Nasdaq Stockholm, and the company is headquartered in Lund, Sweden.

Do you want to get in touch with us?

Please fill out the form and we will contact you as soon as possible.